More details are emerging regarding Eli Lilly's agreement with the US Federal Trade Commission regarding its acquisition of McKesson's pharmacy benefit manager PCS Health Systems, which is considered the USA's largest PBM.
Lilly is acquiring PCS for $4 billion but the deal will be governed by limits agreed with the FTC, which has investigated the proposed acquisition on grounds of it enabling Lilly to act in an anticompetitive nature (Marketletter October 31).
A consent agreement has been approved by the FTC, which requires Lilly to ensure that its drugs do not get unwarranted preferential treatment over competitors' products, maintaining an "open formulary." Lilly has also had to agree to the establishment of a "fire wall" which will ensure that the company will not raid sensitive information on its competitors.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze